Search results
Results from the WOW.Com Content Network
[2] [3] It is a combination of dapagliflozin and saxagliptin. [2] [3] It is taken by mouth. [2] [3] The most common side effects include upper respiratory tract infection (such as nose and throat infections) and, when used with a sulphonylurea, hypoglycaemia (low blood glucose levels). [3]
Dapagliflozin is used along with diet, exercise, and usually with other glucose-lowering medications, to improve glycaemic control in adults with type 2 diabetes. . Dapagliflozin, in addition to other SGLT2-inhibitors, was shown to reduce the rate of decline in kidney function and kidney failure in non-diabetic and type 2 diabetic adults when added to the existing treatment
Less-common side effects can include excess air or gas in your stomach, burping, heartburn, indigestion, fast heartbeat, low blood sugar, low energy and fatigue, or even gallstones, Dr. Comite says.
Some reports in a review supported by Novo Nordisk suggested that semaglutide may decrease the risk of kidney disease over the long term. But there were also a few reports of folks taking GLP-1s ...
Dapagliflozin/metformin was approved for use in the European Union in January 2014, [3] in the United States in February 2014, [5] [6] and in Australia in July 2014. [ 7 ] Adverse effects
The most common side effects include infections of the nose and throat, hypoglycaemia (low blood sugar) when used with a sulphonylurea and effects on the gut such as nausea (feeling sick), vomiting, diarrhoea, abdominal (tummy) pain and loss of appetite.
The first discovered c-glucoside was the drug dapagliflozin. [1] [14] [15] Dapagliflozin was the first highly selective SGLT-2-inhibitor approved by the European Medicines Agency. [16] All SGLT-2 inhibitors in clinical development are prodrugs that have to be converted to its active 'A' form for activity. [9]
A European Medicines Agency review concluded that there is a potential increased risk of lower limb amputation (mostly affecting the toes) in people taking canagliflozin, dapagliflozin and empagliflozin. [17] In August 2018, the FDA issued a warning of an increased risk of Fournier gangrene in patients using SGLT2 inhibitors. [18]